Nilsson A, et al. - Researchers conducted the study for analyzing the impact of statins and other lipid-lowering agents on the development of Graves´ orbitopathy (GO) in patients with newly diagnosed Graves´ disease (GD). The sample involved the full adult population of people residing in Sweden with newly diagnosed GD between 2005 and 2018 (n = 34,894). Data reported that periods of nonusage lasted for a median of 4.3 years (IQR 1.2-8.4), while periods of usage lasted for a median of 4.7 years (IQR 2.0-8.1). Statin treatment in newly diagnosed patients with GD may protect against the development of GO. Statins should be tested as a preventive therapy for GO in newly diagnosed patients with GD in a clinical trial.